Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -0.63% | +3.29% | +53.42% | +72.95% | 56.19B | |
| -0.27% | +0.35% | +40.26% | +79.88% | 54.83B | |
| +1.97% | -1.16% | -21.00% | -13.25% | 23.04B | |
| -2.05% | -2.14% | +0.75% | +413.38% | 22.7B | |
| -0.21% | -0.62% | +20.56% | -10.90% | 20.23B | |
| -1.02% | +1.73% | +25.84% | -30.38% | 17.83B | |
| -0.97% | -0.59% | +33.12% | +550.67% | 15.65B | |
| +5.29% | +1.70% | +185.09% | +333.94% | 15.24B | |
| +0.79% | +0.50% | +22.39% | +184.74% | 14.03B | |
| Average | +0.30% | +0.88% | +40.05% | +175.67% | 26.64B | |
| Weighted average by Cap. | +0.02% | +1.07% | +38.67% | +138.05% |
Employees
51
